Study of E7777 Prior to Kymriah for R/R DLBCL

Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to Tisagenlecleucel (Kymriah) Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are at a higher risk for failure of CAR-T therapy.

Study Overview

• Status: Recruiting
• Conditions: Diffuse Large B Cell Lymphoma; DLBCL; High-grade B-cell Lymphoma; DLBCL Arising From Follicular Lymphoma
• Intervention / Treatment: Drug: E7777

Detailed Description

E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. This trial is designed to augment lymphodepletion prior to CAR-T cells by administration of a targeted immunotoxin against CD25-expressing T-cells. CD25 is expressed at high levels on Tregs but also on activated effector T cells. The use of the CAR-T cell product and associated apheresis and LD chemotherapy is considered standard of care (SOC).

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Cancer Center Clinical Trials Office; Phone Number: 612-676-4200; Email: ccinfo@umn.edu

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Recruiting
      • University of Minnesota, Masonic Cancer Center
      • Principal Investigator: Veronika Bachanova, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of a relapse or refractory (r/r) large B cell lymphoma, for which treatment with Kymriah is planned, including:

  • diffuse large B-cell lymphoma (DLBCL) not otherwise specified,
  • high grade B-cell lymphoma
  • DLBCL arising from follicular lymphoma

• Considered at high risk for progression after CAR-T therapy by meeting one or more of the following factors:

  • refractory to last line of therapy
  • myc over expression >40% in any prior biopsy
  • ≥2 sites of extranodal disease
• Received two or more lines of systemic therapy
• Has secured insurance coverage for Kymriah administration either in the outpatient or inpatient setting.
• Age 18 years or older at the time of signing consent.
• ECOG performance status of 0, 1, or 2

• Adequate bone marrow reserve defined as:

  • Absolute neutrophil count (ANC) > 1,000/mm^3
  • Platelets ≥ 50,000/mm^3 (transfusion support can be provided)
  • Hemoglobin >8.0 mg/dl (transfusion support can be provided) Bone marrow involvement at disease assessment is an exclusion as these patients are at an increased risk of severe CRS and/or neurotoxicity

• Adequate organ function at enrollment and within 14 days of planned E7777 treatment including:

  • renal function: eGFR ≥ 50 mL/min/1.73 m^2
  • liver function: ALT ≤ 3 times the upper limit of normal (ULN) for age, AST ≤ 3 times the ULN, total bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN (if liver is involved by lymphoma, the exception are allowed upon approval of PI)
  • albumin ≥ 3.0 g/dl
• Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea (CTCAE v5) and pulse oxygenation SpO2 > 91% on room air. Pulmonary function tests within 28 days of enrollment: >50% corrected DLCO and FEV1
• Hemodynamically stable and LVEF ≥ 50% confirmed by echocardiogram or MUGA
• Life expectancy ≥12 weeks in the opinion of the enrolling investigator as documented in the medical record
• Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use birth control for at least 30 days after study treatment or at least at least 4 months after the final dose of CY, whichever is longer Female participants: Two forms of birth control, one of which must be a barrier method, for example: use of intrauterine device (IUD) or oral contraceptives, plus a barrier method such as a condom, diaphragm or cervical cap Male participants: If possible to father a child (unless a successful vasectomy with confirmed azoospermia) participant and female partner, must use adequate contraception
• Written voluntary consent prior to the performance of any research related tests or procedures

Exclusion Criteria:

• Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to study enrollment to rule out pregnancy. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
• Known bone marrow involvement, if history of bone marrow involvement must have a BM biopsy to rule-out current involvement
• Prior allogeneic transplant
• Ocular disease or complaints visual acuity impairment, color or shape distortion, or blurred vision - potential participants are required to have an ophthalmological examine as part of screening
• Known CNS involvement by malignancy - if clinically suspicious, must be ruled-out by examination of cerebrospinal fluid (CSF) by flow cytometry
• Uncontrolled active hepatitis B or hepatitis C
• Active or inactive HIV infection
• Untreated active bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to enrollment)
• History of heart failure or pulmonary edema, evidence of pleural effusion or active lower extremity edema
• Uncontrolled unstable angina and/or myocardial infarction within 3 months of enrollment
• Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose level 1 : E7777 at 5 mcg/kg; Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy	Drug: E7777; E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
Experimental: Dose level 1 : E7777 at 7 mcg/kg; Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy	Drug: E7777; E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
Experimental: Dose level 1 : E7777 at 9 mcg/kg; Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy	Drug: E7777; E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
Experimental: MTD from phase 1; Single dose of E7777 (Maximum tolerated dose level identified in phase 1) given on Day -7 two days prior to the start of lymphodepleting chemotherapy	Drug: E7777; E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants experiencing dose limiting toxicity events	Dose Limiting Toxicity (DLT) is defined as any of the following events based on CTCAE v5 from the 1st infusion of E7777 through 21 days after the administration of tisagenlecleucel (~28 days after E7777).; Grade 4 infusion related reaction (IRR) associated with E7777; Grade 4 or Grade 3 capillary leak syndrome (CLS); Grade 3 or 4 liver function test abnormality that do not resolve to <Grade 2 within 5 days; Grade 3 or 4 non-hematologic toxicity event that occurs after the administration of E7777 and before lymphodepleting therapy; Any adverse event that results in a delay of lymphodepleting therapy for more than 72 hours and attributed to E7777; Any Grade 5 adverse event	28 Days Post E7777 infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants experiencing adverse events	Number of participants experiencing adverse events related to E7777 to determine safety of the E7777	100 days Post E7777 infusion
Number of participants experiencing disease free survival (DFS)	Number of participants experiencing disease free survival (DFS) at 1 year	1 year Post E7777 infusion
Number of participants experiencing overall survival (OS)	Number of participants experiencing overall survival (DFS) at 1 year	1 year Post E7777 infusion
Number of non-relapse mortality incidents at day 100	Number of participants experiencing non-relapse mortality at day 100 post E7777 infusion	100 days Post E7777 infusion
Number of Grade 3 or 4 cytokine release syndrome (CRS) incidents	Number of participants experiencing Grade 3 or 4 cytokine release syndrome (CRS) after tisagenlecleucel therapy.	28 Days Post E7777 infusion
Number of Grade 3 or 4 immune effector cell associated neurotoxicity (ICAN) syndrome incidents	Number of participants experiencing Grade 3 or 4 immune effector cell associated neurotoxicity (ICAN) syndrome after tisagenlecleucel therapy.	28 Days Post E7777 infusion

Collaborators and Investigators

• Sponsor: Masonic Cancer Center, University of Minnesota
• Investigators: Principal Investigator: Veronika Bachanova, MD, Masonic Cancer Center, University of Minnesota

Study record dates

Study Major Dates

• Study Start (Actual): June 9, 2021
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: April 19, 2021
• First Submitted That Met QC Criteria: April 19, 2021
• First Posted (Actual): April 22, 2021

Study Record Updates

• Last Update Posted (Actual): July 7, 2023
• Last Update Submitted That Met QC Criteria: July 6, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
• Other Study ID Numbers: 2020LS100; MT2020-27 (Other Identifier: University of Minnesota Masonic Cancer Center)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No